Effective Cancer Targeting Using an Anti‐tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES‐23)

Wakai, Yukiko; Matsui, Junji; Koizumi, Keiichi; Tsunoda, Shin‐ichi; Makimoto, Hiroo; Ohizumi, Iwao; Taniguchi, Kenji; Kaiho, Shin-ichi; Saito, Hiroyuki; Utoguchi, Naoki; Tsutsumi, Yasuo; Nakagawa, Shinsaku; Ohsugi, Yoshiyuki; Mayumi, Tadanori

doi:10.1111/j.1349-7006.2000.tb00920.x

Cited by 21 publications

(8 citation statements)

References 18 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The body's natural protective barriers such as serum nucleases, vascular endothelium, interstitial and oncotic pressure, and the cell wall have made the targeting and treatment of tumor cells particularly challenging (Fig. 19.4) [128,129]. The great obstacle in engineering therapeutics, though, is often not the synthesis and characterization of the agent, but rather overcoming the many biobarriers of the body without damaging the integrity of the payload, in this case miRNA.…”

Section: Negotiating Biological Barriers In Mirna Deliverymentioning

confidence: 97%

“…The promise of in vitro efficacy of miRNA for cancers is dampened by the limitation to effectively deliver the miRNA to the site of interest [125][126][127][128]. The body's natural protective barriers such as serum nucleases, vascular endothelium, interstitial and oncotic pressure, and the cell wall have made the targeting and treatment of tumor cells particularly challenging (Fig.…”

Section: Negotiating Biological Barriers In Mirna Deliverymentioning

confidence: 98%

See 1 more Smart Citation

MicroRNA and Drug Delivery

Fernandez-Moure

Eps

Weiner

et al. 2014

MicroRNA in Development and in the Progression of Cancer

View full text Add to dashboard Cite

The human genome was once thought to be a redundant sequence containing few functional regions coding for proteins. This teaching is being rewritten as we continue to understand the vast complexity of the noncoding regions of the genetic code. These regions we now understand are transcribed into small single-stranded segments or microRNAs (miRNAs) that participate in the regulation of gene expression. miRNAs interact across many pathways and thus have the potential as targets for oncologic therapies. Their efficacy is limited because methods to traverse the many biologic barriers are yet to be developed. In order to achieve effective therapeutic levels at the site of interest, the tumor, the miRNA must be shuttled to the site and simultaneously be protected from the body's defensive mechanisms. To this end, scientists have developed many vehicles for delivery at both the micro-and nanoscale using both synthetic and biologically derived vectors. Viral vectors continue to be the most commonly used vehicles, but are plagued by complications related to the vector itself. These inadequacies led researchers to explore synthetic materials such aspolylactic co-glycolic-acid (PLGA), silicon, gold, and liposomes to overcome the biobarriers of our body. While these vehicles have shown promise, problems such as high clearance rates, poor tumor accumulation and targeting, and adverse reactions have limited their translation into the clinic. In order to overcome these problems, a multistage theory was developed. By decoupling the tasks required of the carrier system, the multistage delivery system is able to simultaneously protect the payload, target the site of interest, and deliver the payload in therapeutic concentrations. This presents a paradigm shift in the concept of drug delivery and may provide the solution to the limited translational gene therapy in oncology.

show abstract

Section: Negotiating Biological Barriers In Mirna Deliverymentioning

confidence: 97%

Section: Negotiating Biological Barriers In Mirna Deliverymentioning

confidence: 98%

MicroRNA and Drug Delivery

Fernandez-Moure

Eps

Weiner

et al. 2014

MicroRNA in Development and in the Progression of Cancer

View full text Add to dashboard Cite

show abstract

“…39 Phagocytosis is an active and highly regulated process which involves specific cell-surface receptors and signaling cascades mediated by Rho-family GTPases. 55 When the drug is chemically conjugated to the polymer, it is either hydrolyzed by an acid-sensitive linker or by enzymatic process and drug molecule is further trapped by the tumor for longer period of time.…”

Section: Active Cancer Targetingmentioning

confidence: 99%

Nanopreparations for Cancer Treatment and Diagnostics

Khandare¹,

Banerjee²,

Minko³

2014

Frontiers in Nanobiomedical Research

View full text Add to dashboard Cite

A number of nanopreparations for cancer treatment have been recently developed. Several advantages of nanoscale-based cancer therapeutics determine a continuous interest to these preparations. Formulation of conventional anticancer drugs as nanopreparations substantially changes their properties and allows for improving their water solubility, stability, anticancer activity, pharmacokinetics and release profi le. It also permits the inclusion of several active components with different functionalities in one delivery system. Modern nanopreparations are capable of delivering hydro-and lipophilic anticancer drugs, nucleic acids, peptides, proteins and almost any other class of therapeutic agents. Such multicomponent multifunctional nanopreparations possess newly enhanced capabilities that exceed the potentials of each individual component applied separately. In addition to traditional chemotherapy, nanopreparations can be designed to be used in several other treatment protocols. They also can be employed as imaging agents to detect primary tumors and metastases. In addition, nanotechnology approach for anticancer formulations allows for the targeting of chemotherapeutic drugs and other active substances (nucleic acids, peptides, etc.) specifi cally to cancer cells therefore enhancing their anticancer activity and limiting severe adverse side effects upon healthy organs and tissues. The present work discusses examples of a few novel approaches to the formulations of nanopreparations for cancer treatment and imaging. Handbook of Nanobiomedical Research Downloaded from www.worldscientific.com by UNIVERSITY OF BIRMINGHAM LIBRARY -INFORMATION SERVICES on 03/22/15. For personal use only.

show abstract

“…49 Also NKT cells have anti-tumor activity in mice, including lung and hepatic cancer metastases when activated by αGal-Cer, by secreting large amounts of IFNγ and IL-4, resulting in activation of other cells of the immune system, including NK cells. 50,51 In a phase I clinical trial with αGalCer in patients with solid tumors, the effect was dependent on the high number of NKT cells present pretreatment. 52 Since the number of NKT cells increases with age and have anti-tumor reactivity, αGalCer could be a potential candidate to activate NKT cells against cancer at older age.…”

Section: Immune Defects In Cancer Patientsmentioning

confidence: 99%

Aging and Cancer Vaccines

Gravekamp

Chandra

2013

Crit Rev Oncog

View full text Add to dashboard Cite

Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by age-related changes of the immune system. Major immune defects at older age are lack of naïve T cells, impaired activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment (TME). Also innate immune responses are affected by aging, but this seems less abundant than adaptive immune responses. In this review we compared various cancer vaccine studies at young and old age, demonstrating the importance of both innate and adaptive immune responses for cancer immunotherapy. Moreover, we found suggestive evidence that innate immune responses could help improve adaptive immune responses through cancer vaccination in old age.

show abstract

Effective Cancer Targeting Using an Anti‐tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES‐23)

Cited by 21 publications

References 18 publications

MicroRNA and Drug Delivery

MicroRNA and Drug Delivery

Nanopreparations for Cancer Treatment and Diagnostics

Aging and Cancer Vaccines

Contact Info

Product

Resources

About